Skip to Main Content

Rise and shine, everyone, another busy day is on the way. Or will it be busy? The summer doldrums seem to have taken hold, suggesting a slightly sluggish pace at times. There is a cure for this, though, and it is called firing up the coffee kettle to brew some cups of stimulation. Your neurons will thank you. Our choice today is salted caramel mocha, a timely taste of the Jersey shore. Meanwhile, we are diligently foraging for items of interest and offering this batch to help you get going. We hope your day is productive and pleasant. And as always, do keep in touch. We want to know all we can about what is going on out there …

Trump administration officials repeatedly stalled a Food and Drug Administration plan to extend safety studies of coronavirus vaccines in fall 2020, as President Trump pressed the agency for a faster timeline so the vaccines could be authorized before Election Day, The Washington Post writes, citing a House committee report. White House officials such as trade adviser Peter Navarro and outside allies such as TV host and physician Mehmet Oz also pressed federal officials in 2020 to authorize the antimalarial drug hydroxychloroquine as a Covid-19 treatment. The report adds new details to the contemporaneous reports about White House efforts to sway the FDA in the first year of the pandemic.


A study found Pfizer’s Covid-19 pill appears to provide little or no benefit for younger adults, while still reducing the risk of hospitalization and death for high-risk older adults, the Associated Press writes. The results from the 109,000-patient Israeli study are likely to renew questions about U.S. government use of Paxlovid, which has become the go-to Covid-19 treatment due to at-home convenience. The Biden administration has spent more than $10 billion on the drug and made it available at thousands of pharmacies through a test-and-treat initiative. The study found the pill reduced hospitalizations among people 65 and older by roughly 75% when given shortly after infection.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment

There was an error saving your display name. Please check and try again.